Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8802620
APP PUB NO 20100197578A1
SERIAL NO

12596323

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);LFB BIOTECHNOLOGIES

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bayry, Jagaadeesh Issy-les-Moulineaux, FR 1 3
Chtourou, Abdessatar Sami Elancourt, FR 15 77
Dasgupta, Suryasarathi Boston, US 1 3
Kaveri, Srinivas Malakoff, FR 4 3
Lacroix-Desmazes, Sébastien Issy-les-Moulineaux, FR 6 4

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 12, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00